Return to homepagePandemic Pact

Imaging Lung Inflammation using PET: The Use of 18F-AzaFol and beyond

  • Funded by Paul Scherrer Institut (PSI)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Paul Scherrer Institut (PSI)

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    Switzerland

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Center for Radiopharmaceutical Sciences (CRS) focuses on the development of new radiopharmaceuticals for positron emission tomography (PET) and other applications in nuclear medicine. Researchers at CRS have previously developed an 18F-based PET tracer (18F-AzaFol) for targeting the folate receptor, which is expressed on tumor cells, but also on activated macrophages involved in inflammatory processes. In a recent clinical study, 18F-AzaFol was investigated regarding its in vivo properties for folate-receptor targeting and assessed with respect to its safety profile in patients (NCT03242993).